Search PAHC
PHIBRO ANIMAL HEALTH CORP
Nasdaq · CIK 1069899
Last close37.24
Daily change+1.37 (3.82%)
10 Years gain+53.80%
Dividends TTM0.48 (+0.00%)
Dividend yield1.34%
Fundamental Analysis
PAHC · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 0630
Fundamental
66.2Momentum
89.9Acceleration
93.9Confidence
100.0Annual Revenue15
Quarterly Revenue52
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth22.2 / 25
Quality16.8 / 25
Capital Efficiency11.4 / 20
Balance Sheet3.5 / 15
Shareholder Economics9.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 1.9751 percentage points.
Operating leverageOperating margin improved by 7.9778 percentage points.
FCF growthFree cash flow grew 217.2198%.
ROIC expansionROIC improved by 10.5613 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM57.45%OK
Revenue CAGR 3Y15.79%OK
Gross Margin32.85%OK
Operating Margin12.24%OK
FCF Margin2.73%OK
FCF Growth217.22%OK
ROIC15.31%OK
Incremental Operating Margin 3Y18.79%OK
Net Debt / CFO6.17xOK
Diluted Share Growth 1Y0.79%OK
SBC / Revenue0.09%OK
SBC / FCF3.4%OK
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 FY Jun 30, 2026 | $1.52B | $512.52M | $194.40M | $68.95M | $9.87M | 33.76% | 12.81% | 0.65% | 55.12% | 40.96M |
| 2026 FY Jun 30, 2025 | $1.30B | $399.94M | $110.47M | $80.12M | $41.83M | 30.85% | 8.52% | 3.23% | 23.66% | 40.68M |
| 2026 FY Jun 30, 2024 | $1.02B | $313.09M | $53.32M | $87.59M | $46.36M | 30.77% | 5.24% | 4.56% | 7.01% | 40.52M |
| 2025 FY Jun 30, 2023 | $977.89M | $298.24M | $71.85M | $13.31M | -$38.48M | 30.5% | 7.35% | -3.94% | 9.39% | 40.5M |
| 2024 FY Jun 30, 2022 | $942.26M | $285.40M | $78.99M | $31.65M | -$5.40M | 30.29% | 8.38% | -0.57% | 17.77% | 40.5M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.47B | sum latest 4 fiscal quarters Revenue | OK | 0001104659-26-056280, 0001104659-25-107001 |
| Revenue Growth TTM | 57.45% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001104659-26-056280, 0001104659-25-107001 |
| Revenue CAGR 3Y | 15.79% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-101493 |
| Revenue CAGR 5Y | 12.74% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001104659-26-101493 |
| Gross Profit CAGR 3Y | 19.78% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-101493 |
| Operating Income Growth | 352.51% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001104659-26-056280, 0001104659-25-107001 |
| FCF Growth | 217.22% | FCF_current / FCF_prior_year - 1 | OK | 0001104659-26-056280, 0001104659-26-010317 |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 32.85% | Gross Profit / Revenue | OK | 0001104659-26-056280, 0001104659-25-107001 |
| Operating Margin | 12.24% | Operating Income / Revenue | OK | 0001104659-26-056280, 0001104659-25-107001 |
| FCF Margin | 2.73% | (CFO - CapEx) / Revenue | OK | 0001104659-26-056280, 0001104659-26-010317 |
| CFO / Net Income | 0.89x | CFO / Net Income | OK | 0001104659-26-056280, 0001104659-26-010317 |
| FCF / Net Income | 0.41x | FCF / Net Income | OK | 0001104659-26-056280, 0001104659-26-010317 |
| ROIC | 15.31% | NOPAT / Average Invested Capital | OK | 0001104659-26-056280, 0001104659-25-107001 |
| Net Debt / CFO | 6.17x | Net Debt / CFO | OK | 0001104659-26-056280, 0001104659-26-010317 |